Compare Gilead Sciences, Inc. (GILD) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Jones Lang LaSalle Inc — how do they compare? Gilead Sciences, Inc. trades at $149.71 (market cap $182.40B), while Jones Lang LaSalle Inc trades at $300.33 (market cap $13.95B). The key difference: Gilead Sciences, Inc. is far larger — about 13.1× Jones Lang LaSalle Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Jones Lang LaSalle Inc for 71 Days on average.
| GILD | JLL | |
|---|---|---|
Market Cap | $182.40B | $13.95B |
Volume | 4,469,821 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $155.80 | $392.79 |
52-Week Low | $116.74 | $280.16 |
Typical Hold Time | 111 Days | 71 Days |
Enterprise Value | $205.46B | $16.71B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
JLL trades at $298.93, up 0.77% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income have grown steadily, reaching $26.12B and $792.10M in 2025, respectively, while valuation ratios like a P/E of 14.54 and P/S of 0.53 appear attractive relative to historical norms.
The outlook is positive, supported by analyst consensus favoring a buy rating and a price target of $450.50, implying significant upside. Risks include exposure to real estate market cycles and competitive pressures, but JLL's expanding cash flow and strategic acquisitions in high-growth areas like data centers provide a solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
